Introducing Idrasil®

The first standardized form of medical cannabis.


Founded
in 2010
Private
Ownership
Manufacturers
of Idrasil®

About us

C3® International, Inc. was formed to leverage first mover advantage and play a leadership role in the emergent cannabinoid therapeutics health sector. C3® is the manufacturer of the Idrasil® Intellectual Property.

Research

Clinical EndoCannabinoid Deficiency (CECD)

Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions.
READ MORE


home_biolab_arrow_left

Executive Staff

C3® International, Inc. is the leader in the emerging cannabinoid sector holding intellectual property on it's flag ship product Idrasil®.